Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

The pharmacy association said it was worried some patients were accessing the drugs inappropriately amid a surge in demand.

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The rise of ultra-thin bodies in Hollywood, fueled by the popularity of weight loss medications, marks a dramatic shift in ...

Weight-loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. The NPA has previously urged patients to ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

Pharmacists say they are aware of people being wrongly prescribed the drugs who have previously had eating disorders, or ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.